Détail - canceropole-wordpress

Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial.

Gounant V, Greillier L, Mascaux C, Pinquie F, Carmier D, Moreau L, Roch B, Debieuvre D, Dhalluin X, Giroux-Leprieur E, Berton E, Rabeau A, Raimbourg J, Dixmier A, Naltet C, Khalil A, Ezzeddine L, El Hajjam M, Langlais A, Morin F, Westeel V, Zalcman G, Duruisseaux M

JTO Clin Res Rep. 2025 12;6(12):100908

Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†.

Zer A, Ahn MJ, Barlesi F, Bubendorf L, De Ruysscher D, Garrido P, Gautschi O, Hendriks LE, Jänne PA, Kerr KM, Mascaux C, Mitsudomi T, Peters S, Rolfo C, Sacher A, Senan S, Ugalde P, Leighl NB,

Ann Oncol. 2025 08 22;:

Advances in lung cancer basic and translational research in 2025 - Overview and perspectives focusing on non-small cell lung cancer.

Mascaux C, Sen T, Sanchez-Cespedes M, Ortiz-Cuaran S, Bossé Y, Dammeijer F, Cavic M, Barr MP, Arulananda S, Armisen R, Berger AH, Bianchi F, Carbone DP, Cerciello F, Lockwood WW, Mitsudomi T, Ohara S, Politi K, Qin S, Roisman LC, Samstein R, Skoulidis F, Tan AC, Thomas A, Zhang J, Wynes MW, John T, Tsao MS,

J Thorac Oncol. 2025 06 3;:

Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study.

Wislez M, Mascaux C, Cadranel J, Thomas QD, Ricordel C, Swalduz A, Pichon E, Veillon R, Gounant V, Rousseau-Bussac G, Madroszyk A, Daniel C, Ravoire M, Metivier AC, Fournel P, Missy P, Morin F, Guisier F, Westeel V

Eur J Cancer. 2025 02 11;219:115301

Sleep quality in lung cancer and specifically non-small-cell lung cancer: a rapid review.

Prieur-Drevon D, Pabst L, Mascaux C, Sauleau EA, Chevalier C, Ruppert E, Calvel L

Support Care Cancer. 2025 01 25;33(2):123

Brief Report: Preventing Infusion-related Reactions With Intravenous Amivantamab: Results From SKIPPirr, a Phase 2 Study.

Spira AI, Paz-Ares L, Han JY, Shih JY, Mascaux C, Roy UB, Zugazagoitia J, Kim YJ, Chiu CH, Kim SW, Nadal E, Gil-Bazo I, Murphy SP, Anderson BG, Xia Y, Wang G, Bauml JM, Chioda M, Simoes J, Mahadevia PJ, Lopes G

J Thorac Oncol. 2025 01 24;:

Central nervous system complications of immune checkpoint inhibitors: a comprehensive review.

Lopes S, Pabst L, Bahougne T, Barthelemy P, Guitton R, Didier K, Geoffrois L, Granel-Brocard F, Mennecier B, Mascaux C, Kremer S, Collongues N

Crit Rev Oncol Hematol. 2024 12 12;:104595

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, Pérol M, Mascaux C, Poddubskaya E, Kitazono S, Hayashi H, Hong MH, Felip E, Hall R, Juan-Vidal O, Brungs D, Lu S, Garassino M, Chargualaf M, Zhang Y, Howarth P, Uema D, Lisberg A, Sands J,

J Clin Oncol. 2024 09 9;:JCO2401544

Impact of adjuvant radiotherapy and chemotherapy on thymoma.

Dumont J, Bou-Gharios J, Keller A, Chambrelant I, Pamart G, Mascaux C, Falcoz PE, Antoni D, Olland A, Pietta GA, Noël G

Cancer Radiother. 2024 01 4;:

Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1.

Besse B, Felip E, Campelo RG, Cobo M, Mascaux C, Madroszyk A, Cappuzzo F, Hilgers W, Romano G, Denis F, Viteri S, Debieuvre D, Galetta D, Baldini E, M Razaq,Robinet G, Maio M, Delmonte A, Roch B, Masson P, Schuette W, Zer A, Remon J, Costantini D, Vasseur B, Dziadziuszko R, Giaccone G,

Ann Oncol. 2023 08 1;:

Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRAS-mutant lung cancer.

Chour A, Denis J, Mascaux C, Zysman M, Bigay-Game L, Swalduz A, Gounant V, Cortot A, Darrason M, Fallet V, Auclin E, Basse C, Tissot C, Decroisette C, Bombaron P, Giroux-Leprieur E, Odier L, Brosseau S, Creusot Q, Gueçamburu M, Meersseman C, Rochand A, Costantini A, Gaillard CM, Wasielewski E, Girard N, Cadranel J, Lafitte C, Lebossé F, Duruisseaux M

J Thorac Oncol. 2023 05 20;:

Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer.

Pabst L, Lopes S, Bertrand B, Creusot Q, Kotovskaya M, Pencreach E, Beau-Faller M, Mascaux C

Int J Mol Sci. 2023 04 20;24(8):

Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.

Lopes S, Pabst L, Dory A, Klotz M, Gourieux B, Michel B, Mascaux C

Front Immunol. 2023 01 26;14:1070076

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.

Adotévi O, Vernerey D, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, Jacquin M, Kaulek V, Boullerot L, Malfroy M, Orillard E, Eberst G, Lagrange A, Favier L, Gainet-Brun M, Doucet L, Teixeira L, Ghrieb Z, Clairet AL, Guillaume Y, Kroemer M, Hocquet D, Moltenis M, Limat S, Quoix E, Mascaux C, Debieuvre D, Fagnoni-Legat C, Borg C, Westeel V

J Clin Oncol. 2022 09 7;:JCO2200096

COVID-19 Outcomes, Patient Vaccination Status, and Cancer-Related Delays during the Omicron Wave: A Brief Report from the TERAVOLT Analysis.

Bestvina CM, Whisenant JG, Torri V, Cortellini A, Wakelee H, Peters S, Roca E, De Toma A, Hirsch FR, Mamdani H, Halmos B, Arrieta O, Metivier AC, Fidler MJ, Rogado J, Presley CJ, Mascaux C, Genova C, Blaquier JB, Addeo A, Finocchiaro G, Khan H, Mazieres J, Morgillo F, Bar J, Aujayeb A, Mountzios G, Scotti V, Grosso F, Geraedts E, Zhumagaliyeva AN, Horn L, Garassino MC, Baena J,

JTO Clin Res Rep. 2022 05 20;:100335

Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.

Gantzer J, Davidson G, Vokshi B, Weingertner N, Bougoüin A, Moreira M, Lindner V, Lacroix G, Mascaux C, Chenard MP, Bertucci F, Davidson I, Kurtz JE, Sautès-Fridman C, Fridman WH, Malouf GG

Oncologist. 2022 Mar 12;:

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).

Popat S, Hsia TC, Hung JY, Jung HA, Shih JY, Park CK, Lee SH, Okamoto T, Ahn HK, Lee YC, Sato Y, Lee SS, Mascaux C, Daoud H, Märten A, Miura S

Oncologist. 2022 Mar 11;:

Direct Targeting Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.

Reita D, Pabst L, Pencreach E, Guérin E, Dano L, Rimelen V, Voegeli AC, Vallat L, Mascaux C, Beau-Faller M

Cancers (Basel). 2022 Mar 4;14(5):

Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.

Paz-Ares L, Gondos A, Saldana D, Thomas M, Mascaux C, Bubendorf L, Barlesi F

Lung Cancer. 2022 Feb 3;167:41-48

A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry.

Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, Leighl NB, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Blaquier JB, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Garrido P, Khan H, Baggi A, Mascaux C, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Métivier AC, Falchero L, Felip E, Genova C, Mazieres J, Tapan U, Brahmer J, Bria E, Puri S, Popat S, Reckamp KL, Morgillo F, Nadal E, Mazzoni F, Agustoni F, Bar J, Grosso F, Avrillon V, Patel JD, Gomes F, Ibrahim E, Trama A, Bettini AC, Barlesi F, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V,

J Thorac Oncol. 2022 Jan 24;:

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Mutations: Results From the IFCT-1703 R2D2 Trial.

Mazieres J, Lafitte C, Ricordel C, Greillier L, Negre E, Zalcman G, Domblides C, Madelaine J, Bennouna J, Mascaux C, Moro-Sibilot D, Pinquie F, Cortot AB, Otto J, Cadranel J, Langlais A, Morin F, Westeel V, Besse B

J Clin Oncol. 2022 Jan 24;:JCO2101455

Re: Two centres' experience with lung cancer resection in patients with advanced non-small-cell lung cancer following treatment with immune checkpoint inhibitors: safety and clinical outcomes.

Mennecier B, Olland A, Mascaux C, Falcoz PE

Eur J Cardiothorac Surg. 2021 12 1;60(6):1306-1307

Assessing therapy response in patient-derived xenografts.

Ortmann J, Rampášek L, Tai E, Mer AS, Shi R, Stewart EL, Mascaux C, Fares A, Pham NA, Beri G, Eeles C, Tkachuk D, Ho C, Sakashita S, Weiss J, Jiang X, Liu G, Cescon DW, O'Brien CA, Guo S, Tsao MS, Haibe-Kains B, Goldenberg A

Sci Transl Med. 2021 Nov 17;13(620):eabf4969

Molecular Mechanism of EGFR-TKI Resistance in -Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.

Reita D, Pabst L, Pencreach E, Guérin E, Dano L, Rimelen V, Voegeli AC, Vallat L, Mascaux C, Beau-Faller M

Cancers (Basel). 2021 Sep 30;13(19):

Evasion before invasion: Pre-cancer immunosurveillance.

Angelova M, Mascaux C, Galon J

Oncoimmunology. 2021 Apr 25;10(1):1912250

TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma.

Staumont B, Jamakhani M, Costa C, Vandermeers F, Sriramareddy SN, Redouté G, Mascaux C, Delvenne P, Hubert P, Safari R, Willems L

Cancers (Basel). 2020 Jun 6;12(6):

Validation of the QR1 Antibody for the Evaluation of PD-L1 Expression in Non-Small Cell Lung Adenocarcinomas.

Brandone N, Mascaux C, Caselles K, Rouquette I, Lantuejoul S, Garcia S

Appl. Immunohistochem. Mol. Morphol.. 2020 Jan;28(1):23-29

[Therapeutic strategies in advanced ALK positive non-small cell lung cancer].

Tiotiu A, Billon Y, Vaillant P, Menard O, Hofman P, Mascaux C

Rev Mal Respir. 2019 Nov 11;:

Immune evasion before tumour invasion in early lung squamous carcinogenesis.

Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G, Buttard B, Rothe F, Willard-Gallo K, Haller A, Ninane V, Burny A, Sculier JP, Spira A, Galon J

Nature. 2019 Jul;571(7766):570-575

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

Jeanson A, Tomasini P, Souquet-Bressand M, Brandone N, Boucekine M, Grangeon M, Chaleat S, Khobta N, Milia J, Mhanna L, Greillier L, Biemar J, Nanni I, Ouafik L, Garcia S, Mazières J, Barlesi F, Mascaux C

J Thorac Oncol. 2019 Jun;14(6):1095-1101

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Mazières J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O

Ann. Oncol.. 2019 May 24;:

Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.

Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N, Bermudez J, Trigui Y, Greillier L, Blanchon M, Boucekine M, Mascaux C, Barlesi F

Clin Lung Cancer. 2019 May;20(3):201-207

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.

Tomasini P, Mascaux C, Jao K, Labbe C, Kamel-Reid S, Stockley T, Hwang DM, Leighl NB, Liu G, Bradbury PA, Pintilie M, Tsao MS, Shepherd FA

Clin Lung Cancer. 2019 May;20(3):e338-e345

[Autoimmune-related bleeding occurring during combined immunotherapy for lung cancer - Case report].

Eberst G, Lakhzoum W, Tomasini P, Andreotti N, Abcaya J, Mascaux C, Barlesi F

Rev Mal Respir. 2018 Nov;35(9):974-977

Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma.

Sharpnack MF, Ranbaduge N, Srivastava A, Cerciello F, Codreanu SG, Liebler DC, Mascaux C, Miles WO, Morris R, McDermott JE, Sharpnack JL, Amann J, Maher CA, Machiraju R, Wysocki VH, Govindan R, Mallick P, Coombes KR, Huang K, Carbone DP

J Thorac Oncol. 2018 10;13(10):1519-1529

The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.

Jao K, Tomasini P, Kamel-Reid S, Korpanty GJ, Mascaux C, Sakashita S, Labbé C, Leighl NB, Liu G, Feld R, Bradbury PA, Hwang DM, Pintilie M, Tsao MS, Shepherd FA

Lung Cancer. 2018 09;123:22-29

Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC).

Dhont L, Pintilie M, Kaufman E, Navab R, Tam S, Burny A, Shepherd F, Belayew A, Tsao MS, Mascaux C

BMC Cancer. 2018 04 16;18(1):429

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, Barlesi F, Mascaux C

Eur Respir Rev. 2018 Mar 31;27(147):

Genomic Testing in Lung Cancer: Past, Present, and Future.

Mascaux C, Tsao MS, Hirsch FR

J Natl Compr Canc Netw. 2018 03;16(3):323-334

Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma.

Imbs DC, El Cheikh R, Boyer A, Ciccolini J, Mascaux C, Lacarelle B, Barlesi F, Barbolosi D, Benzekry S

CPT Pharmacometrics Syst Pharmacol. 2018 01;7(1):42-50

Personalised medicine for nonsmall cell lung cancer.

Mascaux C, Tomasini P, Greillier L, Barlesi F

Eur Respir Rev. 2017 Dec 31;26(146):

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).

Labbé C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, Leighl NB, Feld R, Liu G, Bradbury PA, Kamel-Reid S, Tsao MS, Shepherd FA

Lung Cancer. 2017 09;111:23-29

Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients.

Barlesi F, Imbs DC, Tomasini P, Greillier L, Galloux M, Testot-Ferry A, Garcia M, Elharrar X, Pelletier A, André N, Mascaux C, Lacarelle B, Cheikh RE, Serre R, Ciccolini J, Barbolosi D

Oncotarget. 2017 Jul 18;8(29):47161-47166

EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.

Tomasini P, Serdjebi C, Khobta N, Metellus P, Ouafik L, Nanni I, Greillier L, Loundou A, Fina F, Mascaux C, Barlesi F

Int J Mol Sci. 2016 Dec 18;17(12):

Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.

Martin P, Stewart E, Pham NA, Mascaux C, Panchal D, Li M, Kim L, Sakashita S, Wang D, Sykes J, Friess T, Shepherd FA, Liu G, Tsao MS

Clin Lung Cancer. 2016 09;17(5):375-383.e2

Elderly selection on geriatric index assessment.

Tomasini P, Mascaux C, Barlesi F

Ann Transl Med. 2016 Jun;4(12):245

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes.

Tomasini P, Barlesi F, Mascaux C, Greillier L

Ther Adv Med Oncol. 2016 May;8(3):198-208

The helicase-like transcription factor (HLTF) in cancer: loss of function or oncomorphic conversion of a tumor suppressor?

Dhont L, Mascaux C, Belayew A

Cell. Mol. Life Sci.. 2016 Jan;73(1):129-47

Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models.

Hubaux R, Vandermeers F, Cosse JP, Crisanti C, Kapoor V, Albelda SM, Mascaux C, Delvenne P, Hubert P, Willems L

ERJ Open Res. 2015 Oct;1(2):

Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.

Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, Zhu CQ, Li M, Ng C, Liu N, Pintilie M, Martin P, John T, Jurisica I, Leighl NB, Neel BG, Waddell TK, Shepherd FA, Liu G, Tsao MS

J. Clin. Oncol.. 2015 Aug 1;33(22):2472-80

Bronchial airway gene expression in smokers with lung or head and neck cancer.

Van Dyck E, Nazarov PV, Muller A, Nicot N, Bosseler M, Pierson S, Van Moer K, Palissot V, Mascaux C, Knolle U, Ninane V, Nati R, Bremnes RM, Vallar L, Berchem G, Schlesser M

Cancer Med. 2014 Apr;3(2):322-36

Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the European

Berghmans T, Ameye L, Lafitte JJ, Colinet B, Cortot A, CsToth I, Holbrechts S, Lecomte J, Mascaux C, Meert AP, Paesmans M, Richez M, Scherpereel A, Tulippe C, Willems L, Dernies T, Leclercq N, Sculier JP,

Front Oncol. 2014 ;4:386

Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.

Berghmans T, Ameye L, Willems L, Paesmans M, Mascaux C, Lafitte JJ, Meert AP, Scherpereel A, Cortot AB, Cstoth I, Dernies T, Toussaint L, Leclercq N, Sculier JP,

Lung Cancer. 2013 Nov;82(2):340-5

Adjuvant chemotherapy after pulmonary resection for lung cancer.

Mascaux C, Shepherd FA

Thorac Surg Clin. 2013 Aug;23(3):401-10

Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era.

Brothers JF, Hijazi K, Mascaux C, El-Zein RA, Spitz MR, Spira A

BMC Med. 2013 Jul 19;11:168

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

Peled N, Wynes MW, Ikeda N, Ohira T, Yoshida K, Qian J, Ilouze M, Brenner R, Kato Y, Mascaux C, Hirsch FR

Cell Oncol (Dordr). 2013 Jul;36(4):277-88

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.

Zielinski C, Knapp S, Mascaux C, Hirsch F

Ann. Oncol.. 2013 May;24(5):1170-9

Endobronchial miRNAs as biomarkers in lung cancer chemoprevention.

Mascaux C, Feser WJ, Lewis MT, Barón AE, Coldren CD, Merrick DT, Kennedy TC, Eckelberger JI, Rozeboom LM, Franklin WA, Minna JD, Bunn PA, Miller YE, Keith RL, Hirsch FR

Cancer Prev Res (Phila). 2013 Feb;6(2):100-8

Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Christoph DC, Asuncion BR, Mascaux C, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, Hepp R, Welter S, Stamatis G, Tannapfel A, Schuler M, Eberhardt WE, Hirsch FR

J Thorac Oncol. 2012 Sep;7(9):1440-8

Screening and early detection of lung cancer.

Vansteenkiste J, Dooms C, Mascaux C, Nackaerts K

Ann. Oncol.. 2012 Sep;23 Suppl 10:x320-7

EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.

Mascaux C, Wynes MW, Kato Y, Tran C, Asuncion BR, Zhao JM, Gustavson M, Ranger-Moore J, Gaire F, Matsubayashi J, Nagao T, Yoshida K, Ohira T, Ikeda N, Hirsch FR

Clin. Cancer Res.. 2011 Dec 15;17(24):7796-807

C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib.

CsToth I, Anthoine G, Berghmans T, Mascaux C, Paesmans M, Sculier JP, Meert AP

Anticancer Res.. 2011 Jan;31(1):281-5

Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.

Kato Y, Peled N, Wynes MW, Yoshida K, Pardo M, Mascaux C, Ohira T, Tsuboi M, Matsubayashi J, Nagao T, Ikeda N, Hirsch FR

J Thorac Oncol. 2010 Oct;5(10):1551-8

Early detection and screening of lung cancer.

Mascaux C, Peled N, Garg K, Kato Y, Wynes MW, Hirsch FR

Expert Rev. Mol. Diagn.. 2010 Sep;10(6):799-815

Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.

Hubaux R, Vandermeers F, Crisanti MC, Crisanti C, Kapoor V, Burny A, Mascaux C, Albelda SM, Willems L

Eur. J. Cancer. 2010 Jun;46(9):1724-34

Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Part

Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, Mascaux C, Meert AP, Roelandts M, Scherpereel A, Terrones Munoz V, Sculier JP,

J Thorac Oncol. 2010 May;5(5):612-9

Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.

Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L

Clin. Cancer Res.. 2009 Apr 15;15(8):2818-28

Evolution of microRNA expression during human bronchial squamous carcinogenesis.

Mascaux C, Laes JF, Anthoine G, Haller A, Ninane V, Burny A, Sculier JP

Eur. Respir. J.. 2009 Feb;33(2):352-9

[Study of the genesis of bronchial epidermoid carcinoma: evolution or the expression of proteins, messenger RNAs and microRNAs at all stages of the process of carcinogenesis].

Mascaux C

Bull. Mem. Acad. R. Med. Belg.. 2009 ;164(5-6):247-54

EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: a positive association.

Berghmans T, Mascaux C, Haller A, Meert AP, Van Houtte P, Sculier JP

Lung Cancer. 2008 Oct;62(1):35-44

[Etiology, epidemiology, biology. Lung carcinogenesis].

Mascaux C

Rev Mal Respir. 2008 Oct;25(8 Pt 2):3S32-9

The role of NPM, p14arf and MDM2 in precursors of bronchial squamous cell carcinoma.

Mascaux C, Bex F, Martin B, Burny A, Haller A, Paesmans M, Willard-Gallo K, Ninane V, Sculier JP

Eur. Respir. J.. 2008 Sep;32(3):678-86

Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lu

Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, Scherpereel A, Mascaux C, Moreau M, Roelandts M, Alard S, Meert AP, Patz EF, Lafitte JJ, Sculier JP,

J Thorac Oncol. 2008 Jan;3(1):6-12

Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis.

Berghmans T, Paesmans M, Mascaux C, Martin B, Meert AP, Haller A, Lafitte JJ, Sculier JP

Ann. Oncol.. 2006 Nov;17(11):1673-6

Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results.

Mascaux C, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert AP, Lafitte JJ, Sculier JP

Br. J. Cancer. 2006 Jul 17;95(2):139-45

Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer.

Berghmans T, Mascaux C, Martin B, Ninane V, Sculier JP

Lung Cancer. 2006 May;52(2):219-24

COX-2 expression during early lung squamous cell carcinoma oncogenesis.

Mascaux C, Martin B, Verdebout JM, Ninane V, Sculier JP

Eur. Respir. J.. 2005 Aug;26(2):198-203

Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature.

Berghmans T, Paesmans M, Meert AP, Mascaux C, Lothaire P, Lafitte JJ, Sculier JP

Lung Cancer. 2005 Jul;49(1):13-23

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.

Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert AP, Noel S, Lafitte JJ, Sculier JP

Br. J. Cancer. 2005 Jan 17;92(1):131-9

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis.

Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, Lafitte JJ, Sculier JP

Br. J. Cancer. 2004 Dec 13;91(12):2018-25

Ki67 expression in bronchial preneoplastic lesions and carcinoma in situ defined according to the new 1999 WHO/IASLC criteria: a preliminary study.

Meert AP, Feoli F, Martin B, Verdebout JM, Mascaux C, Verhest A, Ninane V, Sculier JP

Histopathology. 2004 Jan;44(1):47-53

The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature.

Meert AP, Martin B, Paesmans M, Berghmans T, Mascaux C, Verdebout JM, Delmotte P, Lafitte JJ, Sculier JP

Br. J. Cancer. 2003 Sep 15;89(6):959-65

[Immune responses in broncho-pulmonary cancer].

Meert AP, Berghmans T, Mascaux C, Sculier JP

Rev Mal Respir. 2003 Sep;20(4):566-79

Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis.

Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C, Meert AP, Steels E, Vallot F, Verdebout JM, Lafitte JJ, Sculier JP

Br. J. Cancer. 2003 Jul 7;89(1):55-64

Citation indexes do not reflect methodological quality in lung cancer randomised trials.

Berghmans T, Meert AP, Mascaux C, Paesmans M, Lafitte JJ, Sculier JP

Ann. Oncol.. 2003 May;14(5):715-21

Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53.

Mascaux C, Martin B, Verdebout JM, Meert AP, Ninane V, Sculier JP

Eur. Respir. J.. 2003 May;21(5):753-8

Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.

Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, Meert AP, Sculier JP

Lung Cancer. 2002 Nov;38(2):111-21

The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis.

Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, Paesmans M, Steels E, Verdebout JM, Sculier JP

Eur. Respir. J.. 2002 Oct;20(4):975-81

[VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis].

Delmotte P, Martin B, Paesmans M, Berghmans T, Mascaux C, Meert AP, Steels E, Verdebout JM, Lafitte JJ, Sculier JP

Rev Mal Respir. 2002 Oct;19(5 Pt 1):577-84

The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis.

Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM, Lafitte JJ, Mascaux C, Sculier JP

Br. J. Cancer. 2002 Sep 23;87(7):694-701

Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis.

Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Sculier JP

Lung Cancer. 2002 Aug;37(2):115-23

Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis.

Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Jacquy C, Burniat A, Steels E, Vallot F, Sculier JP

Support Care Cancer. 2002 Apr;10(3):181-8

[The role of chemotherapy in the treatment of non-metastatic, non-small cell bronchial cancers].

Sculier JP, Berghmans T, Paesmans M, Branle F, Lemaitre F, Mascaux C, Meert AP, Steels E, Vallot F, Lafitte JJ

Rev Med Brux. 2001 Dec;22(6):477-87

Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis.

Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP

Eur. Respir. J.. 2001 Oct;18(4):705-19

The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature.

Sculier JP, Ghisdal L, Berghmans T, Branle F, Lafitte JJ, Vallot F, Meert AP, Lemaitre F, Steels E, Burniat A, Mascaux C,

Br. J. Cancer. 2001 May 4;84(9):1150-5

Biological basis of anemia.

Bron D, Meuleman N, Mascaux C

Semin. Oncol.. 2001 Apr;28(2 Suppl 8):1-6

Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis.

Meert AP, Paesmans M, Berghmans T, Martin B, Mascaux C, Vallot F, Verdebout JM, Lafitte JJ, Sculier JP

BMC Cancer. 2001 ;1:5

A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis.

Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F, Meert AP, Vermylen P, Sculier JP,

Lung Cancer. 2000 Oct;30(1):23-36

Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment.

Meert AP, Berghmans T, Branle F, Lemaître F, Mascaux C, Rubesova E, Vermylen P, Paesmans M, Sculier JP

Anticancer Res.. ;19(5C):4379-90

Prognostic role of p53 in stage III non-small cell lung cancer.

Berghmans T, Mascaux C, Martin B, Ninane V, Sculier JP

Anticancer Res.. ;25(3c):2385-9

[Docetaxel as salvage treatment for non-small cell lung cancer: implementation study].

Mascaux C, Iannino N, Berghmans T, Meert AP, Sculier JP

Rev Med Brux. ;26(3):153-8

Pr MASCAUX Céline

Fiche personne

Coordonnées

Territoire

Statut

Affiliation

Équipes/plateformes

Recherche

Projets

Publications

Retrouvez aussi